Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24475409 | 1.00 | KDM4E (0.37) | KDM4EHRH3POLBHSD11B1SMN1; SMN2 | |
| SCHEMBL24475382 | 0.90 | KDM4E (0.40) | KDM4EPOLBHSD11B1SMN1; SMN2 | |
| SCHEMBL24475624 | 0.88 | HRH3 (0.36) | KDM4EHRH3POLBCYP2D6KCNH2 | |
| SCHEMBL26949459 | 0.88 | HRH3 (0.36) | KDM4EHRH3POLBCYP2D6KCNH2 | |
| SCHEMBL26948639 | 0.88 | HRH3 (0.36) | KDM4EHRH3POLBCYP2D6KCNH2 | |
| SCHEMBL12748579 | 0.85 | KDM4E (0.50) | KDM4EPOLBHSD11B1SMN1; SMN2 | |
| SCHEMBL684100 | 0.83 | DAO (0.38) | KDM4ESMN1; SMN2DAO | |
| SCHEMBL17482104 | 0.83 | DAO (0.38) | KDM4ESMN1; SMN2DAO | |
| SCHEMBL6660826 | 0.83 | DAO (0.38) | KDM4ESMN1; SMN2DAO | |
| SCHEMBL26762546 | 0.83 | KDM4E (0.36) | KDM4EPOLBHSD11B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | KDM4E 616/4885HRH3 1546/4885POLB 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.